Wednesday, February 1, 2023
Google search engine
HomeMarketResultsDay One Biopharmaceuticals, Inc. to Post FY2027 Earnings of $1.67 Per Share,...

Day One Biopharmaceuticals, Inc. to Post FY2027 Earnings of $1.67 Per Share, HC Wainwright Forecasts (NASDAQ:DAWN)


Day One Biopharmaceuticals, Inc. (NASDAQ:DAWNGet Rating) – Analysts at HC Wainwright issued their FY2027 EPS estimates for shares of Day One Biopharmaceuticals in a analysis word issued on Monday, January ninth. HC Wainwright analyst A. Maldonado expects that the corporate will earn $1.67 per share for the yr. HC Wainwright at present has a “Purchase” score and a $45.00 goal value on the inventory. The consensus estimate for Day One Biopharmaceuticals’ present full-year earnings is ($2.18) per share.

Day One Biopharmaceuticals (NASDAQ:DAWNGet Rating) final introduced its quarterly earnings information on Monday, November seventh. The corporate reported ($0.53) earnings per share (EPS) for the quarter, assembly analysts’ consensus estimates of ($0.53).

A variety of different brokerages have additionally just lately issued reviews on DAWN. Piper Sandler elevated their goal value on shares of Day One Biopharmaceuticals from $40.00 to $45.00 and gave the inventory an “obese” score in a analysis report on Sunday. Needham & Firm LLC started protection on shares of Day One Biopharmaceuticals in a analysis report on Wednesday, December 14th. They set a “purchase” score and a $40.00 goal value for the corporate. The Goldman Sachs Group elevated their goal value on shares of Day One Biopharmaceuticals from $45.00 to $62.00 and gave the inventory a “purchase” score in a analysis report on Monday. Lastly, Financial institution of America started protection on shares of Day One Biopharmaceuticals in a analysis report on Thursday, December 1st. They set a “purchase” score and a $34.00 goal value for the corporate. Six analysis analysts have rated the inventory with a purchase score, Primarily based on information from MarketBeat, Day One Biopharmaceuticals has a mean score of “Purchase” and a mean goal value of $43.50.

Day One Biopharmaceuticals Buying and selling Up 2.6 %

Shares of Day One Biopharmaceuticals stock opened at $21.89 on Tuesday. The corporate has a 50-day easy transferring common of $20.75 and a 200 day easy transferring common of $20.79. Day One Biopharmaceuticals has a 12-month low of $5.44 and a 12-month excessive of $28.35.

Insiders Place Their Bets

In different Day One Biopharmaceuticals information, CEO Jeremy Bender bought 1,513 shares of the inventory in a transaction dated Wednesday, November sixteenth. The shares have been bought at a mean value of $21.46, for a complete transaction of $32,468.98. Following the sale, the chief govt officer now owns 1,217,424 shares of the corporate’s inventory, valued at roughly $26,125,919.04. The sale was disclosed in a authorized submitting with the SEC, which could be accessed by way of this hyperlink. In different Day One Biopharmaceuticals information, CEO Jeremy Bender bought 1,513 shares of the inventory in a transaction dated Wednesday, November sixteenth. The shares have been bought at a mean value of $21.46, for a complete transaction of $32,468.98. Following the sale, the chief govt officer now owns 1,217,424 shares of the corporate’s inventory, valued at roughly $26,125,919.04. The sale was disclosed in a authorized submitting with the SEC, which could be accessed by way of this hyperlink. Additionally, Director Julie Papanek Grant bought 4,358 shares of the inventory in a transaction dated Thursday, December eighth. The inventory was bought at a mean value of $22.08, for a complete transaction of $96,224.64. Following the sale, the director now instantly owns 405,000 shares within the firm, valued at roughly $8,942,400. The disclosure for this sale could be discovered here. Insiders have bought a complete of 119,178 shares of firm inventory valued at $2,458,187 within the final 90 days. 8.70% of the inventory is at present owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds have just lately modified their holdings of the enterprise. Amalgamated Financial institution boosted its stake in shares of Day One Biopharmaceuticals by 21.0% within the third quarter. Amalgamated Financial institution now owns 3,577 shares of the corporate’s inventory valued at $72,000 after buying an extra 620 shares over the last quarter. California State Academics Retirement System boosted its stake in shares of Day One Biopharmaceuticals by 9.5% within the third quarter. California State Academics Retirement System now owns 10,929 shares of the corporate’s inventory valued at $219,000 after buying an extra 944 shares over the last quarter. ACG Wealth purchased a brand new place in shares of Day One Biopharmaceuticals within the 2nd quarter valued at about $32,000. TCI Wealth Advisors Inc. purchased a brand new place in shares of Day One Biopharmaceuticals within the 2nd quarter valued at about $35,000. Lastly, Quantbot Applied sciences LP purchased a brand new place in shares of Day One Biopharmaceuticals within the 2nd quarter valued at about $51,000. Institutional buyers personal 86.08% of the corporate’s inventory.

About Day One Biopharmaceuticals

(Get Rating)

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical firm, develops and commercializes focused therapies for sufferers with genetically outlined cancers. Its lead product candidate is DAY101, an oral brain-penetrant sort II pan-rapidly accelerated fibrosarcoma kinase inhibitor that’s in Section II scientific trial for pediatric sufferers with relapsed/progressive low-grade glioma.

Featured Tales

Earnings History and Estimates for Day One Biopharmaceuticals (NASDAQ:DAWN)

This on the spot information alert was generated by narrative science know-how and monetary information from MarketBeat with a view to present readers with the quickest and most correct reporting. This story was reviewed by MarketBeat’s editorial group previous to publication. Please ship any questions or feedback about this story to contact@marketbeat.com.

Earlier than you take into account Day One Biopharmaceuticals, you may need to hear this.

MarketBeat retains monitor of Wall Avenue’s top-rated and finest performing analysis analysts and the shares they suggest to their shoppers each day. MarketBeat has recognized the five stocks that high analysts are quietly whispering to their shoppers to purchase now earlier than the broader market catches on… and Day One Biopharmaceuticals wasn’t on the checklist.

Whereas Day One Biopharmaceuticals at present has a “Purchase” score amongst analysts, top-rated analysts imagine these 5 shares are higher buys.

View The Five Stocks Here

Beginners Guide To Retirement Stocks Cover



Source link

RELATED ARTICLES
- Advertisment -
Google search engine

Most Popular

Recent Comments